- Home
- BCH vs EXEL Comparison
BCH vs EXEL Comparison
Compare BCH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCH | EXEL |
|---|---|---|
| Founded | 1893 | 1994 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 17.8B |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BCH | EXEL |
|---|---|---|
| Price | $38.72 | $69.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $40.94 | ★ $61.36 |
| AVG Volume (30 Days) | 334.2K | ★ 2.6M |
| Earning Date | 10-30-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.27% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $6.51 | $10.14 |
| Revenue Next Year | $8.01 | $12.56 |
| P/E Ratio | ★ $16.27 | $29.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.60 | $39.71 |
| 52 Week High | $46.77 | $73.44 |
Technical Indicators
Market Signals| Indicator | BCH | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 66.68 |
| Support Level | $37.79 | $55.28 |
| Resistance Level | $39.45 | N/A |
| Average True Range (ATR) | 0.95 | 2.27 |
| MACD | 0.12 | 0.34 |
| Stochastic Oscillator | 65.68 | 64.73 |
Price Performance
Historical ComparisonAbout BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile), Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.